Table 3.
RSK4, CD44 and MMP-9 immunostaining was cross tabulated with. Clinicopathological features of mRCC cases
| n | RSK4 | CD44 | MMP-9 | ||||
|---|---|---|---|---|---|---|---|
| + | – | + | – | + | – | ||
| Age | P = 0.094 | P = 0.482 | P = 0.382 | ||||
| > 58 | 22 (45.8%) | 14 | 8 | 14 | 8 | 21 | 1 |
| ≦58 | 26 (54.2%) | 22 | 4 | 19 | 7 | 23 | 3 |
| Gender | P = 0.098 | P = 0.295 | P = 0.388 | ||||
| male | 41 (85.4%) | 29 | 12 | 27 | 14 | 37 | 4 |
| female | 7 (14.6%) | 7 | 0 | 6 | 1 | 7 | 0 |
| WHO/ISUP nucleolar grade | P = 0.019 | P = 0.026 | P = 0.049 | ||||
| 1–2 | 33 (68.8%) | 28 | 5 | 26 | 7 | 28 | 5 |
| 3–4 | 15 (31.2%) | 8 | 7 | 7 | 8 | 8 | 7 |
| Metastatic sites | P = 0.216 | P = 0.458 | P = 0.658 | ||||
| bone | 23 (23%) | 15 | 8 | 16 | 7 | 21 | 2 |
| lung | 6 (6%) | 6 | 0 | 3 | 3 | 5 | 1 |
| brain | 5 (5%) | 5 | 0 | 3 | 2 | 4 | 1 |
| soft tissue | 10 (10%) | 7 | 3 | 9 | 1 | 10 | 0 |
| others | 2 (2%) | 2 | 0 | 1 | 1 | 2 | 0 |